Dr Amazed - Tesamorelin DECIMATES Visceral Fat and MORE
A primary care doctor explains how tesamorelin works on visceral fat, liver and cognition, why access is restricted, and what risks she flags.
With Dr. Ashley Froese (primary care doctor)
Key moments
Tap a moment to play the video from there.
- 0:00What tesamorelin is said to doFroese introduces tesamorelin as a peptide that she says reduces visceral fat while protecting muscle, and previews liver and cognitive effects.
- 0:30Why visceral fat respondsShe explains that tesamorelin mimics growth hormone-releasing hormone and that visceral fat has more growth hormone receptors than other fat.
- 1:31Full-length versus fragment peptidesFroese contrasts tesamorelin with sermorelin and CJC-1295, saying those are fragments broken down by DPP-4 while tesamorelin is a 44 amino acid analog lasting about 40 minutes.
- 2:36Fat browning and UCP1She describes mitochondrial browning, where white fat is made to act like heat-burning brown fat, and UCP1 letting energy escape as heat.
- 4:15Liver fat and PGC1 alphaFroese cites a 2020 Mass General study reporting a 37% reduction in liver fat over 12 months and links it to PGC1 alpha and new mitochondria.
- 5:38Inflammation and cognitionShe says tesamorelin lowers inflammatory signals from visceral fat and cites a study in older adults showing better executive function and memory.
- 6:09Tracking body compositionFroese recommends measuring visceral fat with a DEXA scan or home analyzer, includes a sponsored segment, and suggests an index of six or less.
- 7:41Why access is restrictedShe traces tesamorelin's FDA approval for HIV lipodystrophy and explains why it is not freely prescribed, noting a $6,000 branded price.
- 9:13Risks of unsupervised useFroese describes fluid shifts, swelling, tingling and carpal tunnel, and warns people with a hidden tumor or cancer history against stimulating growth hormone pathways.
What the video says
Dr. Ashley Froese, a primary care doctor who describes herself as a peptide expert, makes the case for tesamorelin as a peptide aimed at visceral fat. She says it acts on the pituitary by mimicking growth hormone-releasing hormone, and that visceral fat carries more growth hormone receptors than other fat, which she offers as the reason it responds so strongly.
A large part of the video compares tesamorelin with sermorelin and CJC-1295. Froese says those two are fragments of the hormone that are broken down by the enzyme DPP-4, while tesamorelin is a full-length 44 amino acid analog that stays in the body for about 40 minutes. She argues that this longer presence lets it reach receptors outside the brain and pituitary, including those on visceral fat, where she says it promotes fat browning and a heat-producing protein called UCP1.
She then covers a 2020 Mass General study in which, she says, liver biopsies showed a 37% reduction in liver fat after 12 months, and mentions reduced inflammatory signaling and a study in older adults suggesting cognitive benefits. A sponsored segment on the Hum BodyPod analyzer and advice on tracking visceral fat, including a target index of six or less, sits in the middle of the video.
The last third explains why tesamorelin is hard to get: she says it is FDA approved for HIV-associated lipodystrophy, that the branded version costs $6,000, and that a thriving gray market exists. She lists fluid retention, swelling, tingling and carpal tunnel as common effects, and cautions people with a history of cancer or a strong family history of it. She closes by promoting her own peptide course.
On each compound
Tesamorelin0:30
Froese describes it as a full-length 44 amino acid growth hormone-releasing hormone analog lasting about 40 minutes. She says it reduces visceral fat, lowers liver fat and may support cognition, and that it is FDA approved only for HIV-associated lipodystrophy.
See how your DNA reads TesamorelinSermorelin1:31
Froese says sermorelin is a fragment of growth hormone-releasing hormone that DPP-4 breaks down quickly, so she describes it as shorter acting than tesamorelin.
See how your DNA reads SermorelinCJC-12951:31
According to Froese, CJC-1295 is also a fragment-based growth hormone-releasing hormone mimetic that is broken down by DPP-4 and lacks the longer stability she attributes to tesamorelin.
See how your DNA reads CJC-1295What this video doesn’t settle
- Froese's claims about the 37% liver fat reduction, cognitive benefit and reduced inflammation are summarized from memory, with no trial size, dose or full citation given.
- The video does not give dosing, injection schedule or treatment duration for tesamorelin.
- The claim that visceral fat has more growth hormone receptors, and that this explains the effect, is stated without a cited source.
Questions this video answers
How does tesamorelin work on visceral fat?
Froese says tesamorelin mimics growth hormone-releasing hormone, prompting the pituitary to release more growth hormone. She adds that visceral fat has more growth hormone receptors than other fat and that tesamorelin's longer stability lets it reach those receptors directly.
What is the difference between tesamorelin, sermorelin and CJC-1295?
Froese says sermorelin and CJC-1295 are fragments of growth hormone-releasing hormone that DPP-4 breaks down. Tesamorelin, in her description, is a full 44 amino acid analog that lasts about 40 minutes and can act beyond the pituitary.
Why is tesamorelin hard to get a prescription for?
Froese says it is FDA approved as a specialty drug only for HIV-associated lipodystrophy, with a branded price of $6,000. She explains this came from a company needing a specific diagnosis to prove the drug worked.
What side effects of tesamorelin does Froese mention?
She says it can cause fluid shifts, with swelling and tingling in the hands and feet, and that carpal tunnel is fairly common. She also cautions people with a hidden tumor or a personal or strong family history of cancer.
Video by This Is Not Covered - Dr. Ashley Froese on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
